Participating in the “Dr. Answer 2.0” AI precision medicine solution development project

AIDOT is launching development of software to predict thyroid cancer recurrence together with the Medical AI Team at Chungbuk National University Hospital.

AIDOT announced on the 10th that it will participate—together with Chungbuk National University Hospital’s Medical AI Team—in the Ministry of Science and ICT-led project to develop the “Dr. Answer 2.0” AI precision medicine solution, and will develop software to predict recurrence of thyroid cancer by 2024.

As the second project in the Dr. Answer series, Dr. Answer 2.0 aims to develop AI medical software for 12 diseases, including pneumonia and liver disease, with the goal of improving the quality of medical services and reducing medical costs—thereby enhancing public health and quality of life.

Among the 12 diseases selected as targets under Dr. Answer 2.0, AIDOT will develop software that predicts recurrence of thyroid cancer. Accordingly, it plans to complete development of a thyroid cancer recurrence prediction model and a software prototype by 2023, and then integrate it with its AI carotid ultrasound screening system, which is currently undergoing regulatory approval, to begin full-scale commercialization starting in 2024.

Lee Kang-bin, team leader of the Service Development Team at AIDOT’s R&D Institute and the principal investigator of the research, said, “Thyroid cancer has a high probability of recurrence and can also easily metastasize to other sites,” adding, “I hope this project will serve as an opportunity to respond quickly to thyroid cancer recurrence so that many patients can be freed from worries about recurrence.”

Meanwhile, in addition to the thyroid cancer recurrence prediction program, AIDOT has developed and is pursuing commercialization of △“Cerviray AI,” an AI cervical cancer diagnostic system △“SONO dot AI,” a carotid diagnostic system for stroke prevention △“GIGA dot AI,” a real-time gastroenterology endoscopy screening system. The company has also been selected as an operator for the HIRA demonstration special-provisions project and as a Gangwon Province regulatory free-zone project operator, through which it developed an AI ureteral stone system and an AI early liver disease pre-diagnosis system.

Published: May 10, 2022 / Pharmnews / Reporter Kim Tae-il